52 CD150 as a potential marker for alloactivated CD4+25+ regulatory T cells  by Browning, M.B. et al.
Poster  P resentat ions  - Sess ion  I 
5O 
OUTCOMES OF HLA IDENTICAL SIBLINGS ARE COMPARABLE TO 
UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION 
(HSCT) IN ADULTS WITH ACUTE MYELOID LEUKEMIA 
Basara, N.; Kraut, L.; Gue,zelmam~, S.; Pohl, H.; Kiehl, 3/I.G.; 
Fauser, A.A. Bk/IT Unit, Clinic for B3/IT mzd Hematology/Ollcology, 
Idar-Obersteh% Ge~w~mzy. 
The results comparing unrelated HSCT to HLA identical sib- 
lings HSCT in adults with AML are still only occasionally 
reported. Between 1994 and 2000, 68 pts with primary AML 
received an unrelated HSCT in our center. We analyzed the 
overall and disease-free survival in this group of patients. The 
outcome of this group of pts was compared to the results of 65 
patients with AML treated with HSCT from related onors. 
Both groups were matched with regard to age, FAB classifica- 
tion, stage of the disease and HLA-compatibility of the donor. 
Median age of pts was 36 (range 16 to 55;.nnrelated) and 40 
(range 22 to 6i; related) years, respectively. The male to female 
ratio was 33/32 and 33/35, respectively. Conditioning for HSCT 
consisted either of a busulfan-based regimen in 65 pts (30 relat- 
ed, 35 unrelated) or total body irradiation in 68 pts (35 related, 
33 unrelated). Graft-versus-host disease prophylaxis consisted of 
cyclosporine and prednisolone without (related transplants, 
72 %) or with methotrexate (unrelated transplants, 84%). Seven- 
ty nine % of pts with unrelated HSCT and 77% of pts with 
related HSCT have received an HLA-A, -B, and -DRB1 loci 
matched transplants. Median and average post-transplant follow- 
up was 8 and 18 months, respectively, with the longest overall 
survival being 6 years. Disease free survival (DFS) in the unrelat- 
ed group of pts at 5 years was 54% for transplants ransplanted 
in first complete remission (CRI) (n=16), 47% in second CR 
(CR2) (n= 16) and 13 % for advanced stages of the disease (>CR2) 
(n=36). Overall survival at 5 years was 47% (CRI), 36% (CR2) 
and 9% (>CR2). The cumulative incidences for relapse in the 
unrelated group were 13%, 19% and 44% for the three groups, 
respectively. DFS in pts treated with related transplants at 5 
years was 42% (CR1) (n=25), 31% (CR2) (n=9) and 25% (CR2), 
(n=31). The cumulative incidences for relapse in related group 
were 20%, 22% and 48% for the three groups, respectively. In
conclusion, the results of this comparative study confirm that 
unrelated HSCT is an important treatment option for patients 
with standard and high-risk AML in CR. Thus the indications 
for a MUD in adults with AML could be the same as the indica- 
tion for a related HSCT and not only indicated in CR2 and in 
advanced phase of the disease. 
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MISMATCHED UNRELATED CORD BLOOD TRANSPLANTATION FOL- 
LOWING REDUCED-INTENSITY CONDITIONING REGIMEN (RICBT) IN 
ADULTS WITH HEMATOLOGICAL DISEASES AND SOLID MALIGNANCIES 
1~q7, Kd; Kusunff, E. J; ~[iyakoshi, Sd; Ueya~na, if.l; Kami, JV[.2; JTlori- 
7zag~, S.I; Muto, Y.: 1. Toranomon Hospital, Minato-ku TORTO, 
ffapm~; 2. Natiomd Cancer Center Hospital, Chuo-ku TOATO, Japan. 
Background: Reduced-intensity stem cell transplantation 
(RIST) is a curative treatment for various hematological malig- 
nancies among eider patients and those with organ dysfunction. 
RIST is also investigated against some solid tumors. However, 
limited availability of an HLA-matched sibling" donor requires 
alternative stem cell sources. Cord blo6d may serve as an effec- 
tive source of stem cells, thereby broadening the scope of 
patients who may benefit from RIST. We report seven cases of 
patients who received reduced-intensity conditioning cord blood 
transplantation (RICBT). Patients and methods: Between Jam> 
ary and October 2002, seven patients with advanced hematologi- 
cal diseases received RICBT using 2-3 antigens mismatched cord 
blood. Median nmnber of nucleated cells infused was 3.3 (2.3- 
4.7) x 10^7/kg. Conditioning regimen was consisted of fludara- 
bine 25 rag/m^2 for five days, melphalan 100 to 140 rag/m^2 for 
one day, and with/without TBI (Table 1). GVHD prophylaxis 
was intravenous cyclosporine 3mg/kg alone. G-CSF was contin- 
ued until neutrophil engraftment. Chimerism was determined by 
either FISH using sex chromosomes or the STR-PCR method. 
Result: Results are summarized in Table l(Abbreviations: CR = 
complete remission, PD = progressive disease, NE = not evalu- 
able). Except wo patients (patient No.4 who developed hypera- 
cute GVHD, followed by non-relapse mortality due to MOF, 
and patient No.6 who does not achieve ngraftment on day 17), 
stable engraftment was established in the remaining five patients. 
Acute GVHD did not develop in two patients who survived 
more than 100 days. Chronic GVHD (Bronchiolitis obliterans: 
BO) developed in one of two evaluable patients. Among the five 
patients who had evaluable lesions before transplant, the 
responses following RICBT were CR (n=2), PD (n=2), and 
unevalnable due to death before engraftment (n=l). Conclusion: 
Stable engraftment and donor type chimerism were established 
in five of the seven patients receiving RICBT, suggesting that 
cord blood can be an alternative source in RIST. Since a clinical 
manifestation of GVHD was not essential for disease-free sur- 
vival and possibly induction of a GVL effect, the control of 
GVHD and reduced-transplant related toxicity with the 
reduced-intensity transplant approach will be the focus of fur- 
ther investigation. 
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CDI50 AS A POTENTIAL MARKER FOR ALLOACTIVATED CD4+25 ÷ 
REGULATORY T CELLS 
Browning, 3/I.B.; I, Vooclliff J.E.; Konkol, M.C.; Pati, N.T.; 'l)'mtt, 
R.L.; fro h~zson, 13. D. Medical College of H<iscozM~% 3,Iilwaukee, ~'VI. 
We are currently investigating whether allospecific CD4+25 + 
regulatory T cells can be identified for potential use in treating 
graft-versus-host disease. Freshly-isolated human CD4+25 + T 
cells were found to be hyporesponsive to allostimulation and 
variable in their ability to suppress syngeneic responder T cells 
in mixed lymphocyte reaction (MLR) cultures. However, after 
5-7 days of coculture with allogeneic stimulator cells, CD4+25 + 
T cells remained hyporesponsive to restimulation, but they 
became highly suppressive when added to primary MLR cul- 
tures. Using lnicroarray analysis, we observed that gene expres- 
sion for the activation molecule CD150 (or SLAM) is upregu- 
lated on CD4+25 + cells as compared to CD4+25 - cells. 
However, CD150 cell surface expression levels on these two 
cell populations were not different, and only low levels of 
CD150 were observed on 5-20% of freshly-isolated cells. After 
coculture with irradiated allogeneie stimulator cells for 5 days, 
increased CD150 expression levels and higher percentages (20- 
40%) of CD150 ÷ cells were seen for both CD4+25 + and 
CD4+25 cells. Addition of IL-2 to the cocuhures further 
increased the percentages of CD150 + cells. The CD150 ÷ cells 
were larger, as indicated by increased forward light scatter, 
suggesting that these cells were in an activated blast state. Ini- 
,tia] functional studies indicated that when CD4+25 + T cells 
were cultured for 5 days with allostimulator cells and then sep- 
arated into CDI50 + and CD15@ subsets by fluorescence acti- 
vated cell sorting, suppressive activity was enriched in the 
CD150 + cell fraction and decreased in the CD150 fraction as 
compared to unseparated cells. These results suggest that 
CD 150 may be a useful marker for identification f alloactivat- 
ed CD4+25 + regulatory T cells. 
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